Land: USA
Sprog: engelsk
Kilde: NLM (National Library of Medicine)
NIFEDIPINE (UNII: I9ZF7L6G2L) (NIFEDIPINE - UNII:I9ZF7L6G2L)
American Health Packaging
NIFEDIPINE
NIFEDIPINE 30 mg
PRESCRIPTION DRUG
Abbreviated New Drug Application
NIFEDIPINE EXTENDED RELEASE- NIFEDIPINE TABLET, EXTENDED RELEASE AMERICAN HEALTH PACKAGING ---------- NIFEDIPINE EXTENDED-RELEASE TABLETS, USP 30 MG AND 60 MG 8297932/1015OS RX ONLY FOR ORAL USE DESCRIPTION Nifedipine Extended-Release Tablets, USP are an extended release tablet dosage form of the calcium channel blocker nifedipine. Nifedipine is 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2- nitrophenyl)-dimethyl ester, C H N O , and has the structural formula: Nifedipine, USP is a yellow crystalline substance, practically insoluble in water but soluble in ethanol. It has a molecular weight of 346.3. Nifedipine extended-release tablets contain either 30 or 60 mg of nifedipine for once-a-day oral administration. Inert ingredients in the formulation are: colloidal silicon dioxide, hypromellose, lactose monohydrate, magnesium stearate. The inert ingredients in the film coating are: hypromellose, polydextrose, polyethylene glycol 8000, triacetin, yellow iron oxide and titanium dioxide. Product meets USP dissolution test #6. CLINICAL PHARMACOLOGY Nifedipine, USP is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist) which inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. The contractile processes of vascular smooth muscle and cardiac muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. Nifedipine selectively inhibits calcium ion influx across the cell membrane of vascular smooth muscle and cardiac muscle without altering serum calcium concentrations. MECHANISM OF ACTION The mechanism by which nifedipine reduces arterial blood pressure involves peripheral arterial vasodilatation and, consequently, a reduction in peripheral vascular resistance. The increased peripheral 17 18 2 6 vascular resistance, an underlying cause of hypertension, results from an increase in active tension in the vascular smooth muscle. Studies have demonstrated that the increase in active tensio Læs hele dokumentet